Clinical trial · Interventional
Perfusion and Diffusion Magnetic Resonance Imaging, and Phosphorylation of Circulation Endothelial Cells to Determine Anti-anogenic Effect of Chemotherapeutic Regimens in Colorectal Liver Metastasis Patients
Study of Perfusion and Diffusion Magnetic Resonance Imaging, and Phosphorylation of Circulation Endothelial Cells to Determine Anti-angiogenic Effect in Patients With Colorectal Liver Metastasis in Chemotherapeutic Regimens Including Avastin
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of our study is to establish the accuracy of the perfusion MRI parameters and the availability of the VEGFR2 signaling assay using phosphospecific flow cytometry in predicting the response of liver metastasis from colorectal cancer to treatment with antiangiogenic agent.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| DCE MRI | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Standard Chemotherapy with Avastin
- interventionNames
- Procedure: DCE MRI
- type
- ACTIVE_COMPARATOR
- label
- Standard Chemotherapy only
- interventionNames
- Procedure: DCE MRI
Primary outcomes (1)
- measure
- MR perfusion parameter
- timeFrame
- 3 days after administrating avastin
- description
- MR perfusion parameter(Ktrans, Kep, Ve)
Secondary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 20 Years
Show eligibility criteria text
Inclusion Criteria: * Patients who have single or multiple liver metastasis from colorectal cancer * Patients willing to undergo the study procedure * Patients who are fully informed about the study and have signed the informed consent form * 60 patients (30 patients who will get antiangiogenic agent(Avastin) combined chemotherapy and 30 patients who will get chemotherapy without antiangiogenic agent) Exclusion Criteria: * Patients (men or women) under 20 years of age * Patients who have previously entered this study * Patients who have received or will receive any investigational drug 48 hours before injection of the study drug or during study participation * Women who are pregnant, lactating or who are of childbearing potential and have not had a negative pregnancy test at baseline visit * Patients not eligible to contrast media injection according to product labeling * Patients with a contraindication for MRI or CT * Patients with impaired renal function (e.g. acute renal failure) or patients on dialysis
References
Publications (0)
Data not yet available